BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 48,316 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 48,316 shares of the stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $312.25, for a total transaction of $15,086,671.00. Following the completion of the sale, the chief executive officer directly owned 9,180 shares in the company, valued at approximately $2,866,455. The trade was a 84.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

• On Tuesday, July 21st, John Oyler sold 61,397 shares of BeOne Medicines stock. The shares were sold at an average price of $317.67, for a total transaction of $19,503,984.99.
• On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The shares were sold at an average price of $298.34, for a total transaction of $3,489,981.32.
• On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The stock was sold at an average price of $304.35, for a total transaction of $14,767,062.00.
• On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The stock was sold at an average price of $305.95, for a total transaction of $44,626,172.95.
• On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The stock was sold at an average price of $273.78, for a total transaction of $933,589.80.
• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The shares were sold at an average price of $265.55, for a total transaction of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The shares were sold at an average price of $257.24, for a total transaction of $501,360.76.
• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The stock was sold at an average price of $270.56, for a total transaction of $1,336,566.40.

BeOne Medicines Trading Up 1.4%

Shares of ONC stock opened at $330.46 on Wednesday. The company has a market capitalization of $36.26 billion, a PE ratio of 73.93 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $253.95 and a 52-week high of $385.22. The business’s fifty day moving average is $292.77 and its 200 day moving average is $309.37. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64.

BeOne Medicines (NASDAQ:ONC) last posted its earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The business had revenue of $1.51 billion during the quarter. On average, equities research analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 5.93 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE purchased a new stake in shares of BeOne Medicines in the 2nd quarter valued at $67,657,000. Man Group plc purchased a new position in BeOne Medicines in the 2nd quarter worth $59,031,000. BNP Paribas Financial Markets purchased a new position in BeOne Medicines in the 2nd quarter worth $38,337,000. First Trust Advisors LP lifted its stake in BeOne Medicines by 91.9% in the first quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock worth $71,696,000 after purchasing an additional 115,601 shares during the last quarter. Finally, Qube Research & Technologies Ltd bought a new stake in BeOne Medicines in the second quarter worth $26,034,000. 48.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 18th. Nomura upgraded shares of BeOne Medicines to a “strong-buy” rating in a research report on Monday. JPMorgan Chase & Co. boosted their price target on shares of BeOne Medicines from $415.00 to $425.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Zacks Research cut shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 3rd. Finally, Royal Bank Of Canada increased their price target on shares of BeOne Medicines from $436.00 to $451.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, BeOne Medicines has a consensus rating of “Moderate Buy” and a consensus target price of $394.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.